Affordable Access

Anti-U3 snRNP antibodies in localised scleroderma

Authors
Publication Date
Source
PMC
Keywords
  • Correspondence
Disciplines
  • Medicine

Abstract

133202_web Our Three-Fold Mission Is Support, Education and Research PULMONARY HYPERTENSION IN SCLERODERMA A publication of Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923 800-722-HOPE (4673) www.scleroderma.org www.facebook.com/sclerodermaUS www.twitter.com/scleroderma April 2014 be taken by pregnant women, or women thinking of becoming pregnant. Other side effects may include edema and nasal congestion. Macitentan Macitentan (Opsumit®) is the latest drug in the ERA class to be approved to treat PAH. Macitentan is approved for treatment of PAH to delay disease progression defined as death, initiation of intravenous (IV) or subcutaneous prostacyclin drugs, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). The need for PAH hospitalization was also reduced. Like other ERA drugs, macitentan is contraindicated in pregnancy because it may harm the developing fetus, and females of reproductive potential should be counseled on the use of reliable contraception and have a negative pregnancy test prior to initiating therapy and monthly thereafter. Phosphodiesterase-V (PDE-V) Inhibitors Sildenafil Sildenafil was previously approved for the treatment of erectile dysfunction under the trade name of Viagra®. It is also approved for the treatment of PAH, under the trade name of Revatio®. Sildenafil has been shown to improve exercise capacity, pulmonary artery pressure, and functional class in patients with PAH. Potential side effects include flushing, dyspepsia, visual changes, and nosebleeds. Tadalafil Tadalafil (Adcirca®) is approved as a once-daily oral therapy for the treatment of PAH, and is indicated to improve exercise capacity in PAH patients. Side effects include headache, stomach upset, back pain, muscle pain, stuffy or congested nose, flushing, pain in arms or legs, or vision change. Guanylate Cyclase Stimulators

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F